Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now
Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High?
Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics Q3 EPS $(0.38) Beats $(0.95) Estimate
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
Cartesian Therapeutics Announces New Employment Inducement Grants
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.